Fiscal Year 2009 Annual Review of Nasal Allergy Products

Oklahoma Health Care Authority April 2010

Current Prior Authorization of Nasal Allergy Products

1. The following criteria are required for approval of a Tier 2 product:

- a. Documented adverse effect or contraindication to the preferred products.
- b. Failure with Tier 1 medications defined as no beneficial response after at least three weeks use of each during which time the drug has been titrated to the recommended dose. All available Tier 1 corticosteroids should be tried prior to approval of higher Tiered products).

2. The following criteria are required for approval of a Tier 3 product:

- a. All Tier 2 criteria must be met.
- b. Failure with all available Tier 2 products defined as no beneficial response after at least three weeks use of each during which time the drug has been titrated to the recommended dose.
- 3. Approvals will be for the duration of three months, except for members with chronic diseases such as asthma or COPD, in which case authorizations will be for the duration of one year.
- 4. All products also have quantity limits in place, based on the FDA approved maximum dose.

Nasal Allergy Products						
Tier 1	Tier 2	Tier 3				
Corticosteroids						
Fluticasone(Flonase®)	Fluticasone (Veramyst™)	Ciclesonide (Omnaris™)				
Flunisolide (Nasalide®, Nasarel™)	Beclomethasone (Beconase® AQ)	Budesonide (Rhinocort® AQ)				
	Triamcinolone (Nasacort® AQ)	Mometasone (Nasonex®)				
Other						
Ipratropium bromide (Atrovent®)	Olapatadine (Patanase®)					
	Azelastine (Astepro®)					
And the control of the Control	Azelastine (Astelin®)					


Mandatory generic plan applies, Current tiers based on Supplemental Rebate participation

Utilization of Nasal Allergy Products


Comparison of Fiscal Year Utilization

Fiscal Year	Members	Claims	Paid	Paid/Claim	Perdiem	Units	Days
2008	33,017	66,231	\$4,373,469.62	\$66.03	\$2.00	1,054,835	2,181,547
2009	36,184	68,243	\$4,100,725.91	\$60.09	\$1.85	1,056,764	2,218,159
% Change	9.60%	3.00%	-6.20%	-9.00%	-7.50%	0.20%	1.70%
Change	3,167	2,012	-\$272,743.71	-\$5.94	-\$0.15	1,929	36,612

Demographics of Members Utilizing Nasal Allergy Products: FY 2009




Top Prescribers of Nasal Allergy Products by Number of Claims: FY 2009



There were a total of 1,951 petitions submitted for this PBPA category during fiscal year 2009. The following shows the status of the submitted petitions.





Conclusion and Recommendations

The College of Pharmacy recommends no changes to this category at this time. The prior authorization of Singulair® resulting in the topical nasal corticosteroid trial requirement that was implemented January 2009 did not significantly increase costs associated with this category. There was a slight increase in utilization which may be due to the trial requirement or a general increase in members covered by SoonerCare.

Chemical Name	Brand Name	Claims	Members	Amount Paid	Days/ Claim	Claims/ Member	Per- diem	% Paid
Fluticasone	FLUTICASONE SPR 50MCG	25,528	14,633	\$362,119.06	32	1.74	\$0.44	8.83%
Fluticasone	VERAMYST SPR 27.5MCG	18,044	11,274	\$1,665,822.37	32	1.6	\$2.85	40.62%
Mometasone	NASONEX SPR 50MCG/AC	11,995	6,492	\$1,038,943.63	34	1.85	\$2.58	25.34%
Triamcinolone	NASACORT AQ 55MCG/AC	7,426	4,362	\$697,851.67	33	1.7	\$2.85	17.02%
Azelastine	ASTELIN NASA SPR 137MCG	1,544	916	\$134,603.31	31	1.69	\$2.82	3.28%
Flunisolide	FLUNISOLIDE SPR 0.025%	1,260	841	\$31,367.62	31	1.5	\$0.80	0.76%
Flunisolide	FLUNISOLIDE SPR 29MCG	574	366	\$24,126.79	30	1.57	\$1.40	0.59%
Olopatadine	PATANASE SPR 0.6%	439	321	\$38,756.06	32	1.37	\$2.76	0.95%
Azelastine	ASTEPRO SPR 137MCG	423	350	\$37,751.16	34	1.21	\$2.61	0.92%
Ipratropium	IPRATROPIUM SPR 0.03%	271	194	\$4,294.22	31	1.4	\$0.51	0.10%
Ciclesonide	OMNARIS SPR	209	138	\$18,100.10	30	1.51	\$2.84	0.44%
Beclomethasone	BECONASE AQ SUS 0.042%	201	108	\$28,564.28	31	1.86	\$4.55	0.70%
Budesonide	RHINOCORT SUS AQUA	166	67	\$15,317.96	31	2.48	\$2.93	0.37%
Ipratropium	IPRATROPIUM SPR 0.06%	159	111	\$2,887.05	25	1.43	\$0.72	0.07%
Flunisolide	NASAREL SPR 29MCG	3	2	\$167.69	30	1.5	\$1.86	0.00%
Beclomethasone	VANCENASE AQ SPR .084% DS	1	1	\$52.94	30	1	\$1.76	0.00%
	Totals		36,184*	\$4,100,725.91	33	1.89	\$1.85	100.00

^{*}Total Number of Unduplicated Members